# A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

> **NCT07502560** · PHASE4 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 33609 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Recombinant zoster vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07502560
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2030-04-01
- **Final completion:** 2037-03-31
- **Target enrollment:** 33609 (ESTIMATED)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502560, "A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07502560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*